Aims & Scope:

Protein kinase is among largest protein families and having important role in cell signaling. The 518 protein kinases encoded in the human genome are regulating different cellular processes. Around 25 kinase inhibitors have been approved till date while many are under clinical trials. Thus by regulating protein kinase number of potential therapeutic agents could be designed against different ailments. Due to its importance, kinase inhibitors are involved in treatment of number of diseases like neurodegenerative disorders, cardiovascular diseases, cancer etc. This thematic issue will cover expose the versatility of protein kinase as drug target.

Keywords: Protein Kinase, inhibitors, cancer, diabetes, neurodegenerative disorder.

Sub-topics:

The sub-topics to be covered within the issue should be provided:

1. Kinase inhibitors in cancer drug designing
2. Kinase inhibitors: in silico drug designing
5. Kinase inhibitors in anti diabetic therapy.

Tentative titles of the articles and list of contributors:

Dr. Pradeep Kumar
Pharmaceutics, Department of Pharmacy and Pharmacology, University of the Witwatersrand, Johannesburg, South Africa.
Email: pradeep.kumar@wits.ac.za
Title: “Can nanomedicinal approaches provide an edge to the efficacy of tyrosine kinase inhibitors?”

Dr. Kamal Dua
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.
Email: Kamal.Dua@uts.edu.au
Title: “Recent Trends in rationally designed molecules as kinase inhibitors”.

Prof. Patrick T. Flaherty
Division of Medicinal Chemistry, School of Pharmacy, Duquesne University, 410A Mellon Hall, 600 Forbes Avenue, Pittsburgh, PA 15282, United States
Email: flahertyp@duq.edu
Title: “MEKS inhibitors”.

Prof. Vikas Sharma
Lovely School of Pharmaceutical Sciences, Lovely Professional University,
Phagwara, Punjab-144411, India Email: vikaspharma26@gmail.com
Title: “Anticancer effects of heterocyclic derivatives as kinase hinge binders.”

Schedule:

-Thematic issue submission deadline: 30th September 2021

Contacts:

Guest Editor Name: Dr. Vikas Sharma
Affiliation: Lovely School of Pharmaceutical Sciences,
Lovely Professional University,
Phagwara, Punjab-144411, India.
Email: vikaspharma26@gmail.com